Search

EHA Awards

Nominations closed on January 15, 2025. Since 1999, EHA has used its awards program to acknowledge successes within our global community of hematologists. You can read about our many prestigious winners in the previous awards section.

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more

EHA Innovation Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Highlights of the EHA-EMA Joint Symposium on RWE

The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.

Read more

European Board for Accreditation in Hematology

Current committee members
Peter van den Burg, The Netherlands (Chair and ISBT representative—transfusion medicine)
Michelle Kenyon, United Kingdom (EBMT Nurses Group representative—Specialized Hematology Professional)
Fionnuala Ní Áinle, Ireland (ISTH representative—thrombosis and hemostasis)
Annalisa Ruggeri, Italy (Representative, clinical hematology)
Isabel Sanchez-Ortega, Spain (EBMT representative)
Ana Filipa Marques…

Read more

Selection panel and principles

Selection panel
EHA Board — Margarita Guenova
EHA Board — Jose Maria Ribera
Community and Stakeholder Committee — Darko Antic
Diversity, Equity, and Inclusion Taskforce — Mihnea-Alexandru Gaman
Education Committee — Jose Tomás Navarro Ferrando
European Affairs Committee — Julio Delgado
Patient Advocacy Committee — Derek Elston
Research…

Read more

Abstract submission

Abstract procedureThe official abstract submission closed on March 1, 2025 (23:59 CET).

Read more

First CMML guidelines produced by EHA, now available

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Read more